Advertisement
ADVANCED SEARCH

This Article Full Text Full Text (PDF) Correction (v170,p1082) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montessori, V. Articles by Montaner, J. S.G. Search for Related Content PubMed PubMed Citation Articles by Montessori, V. Articles by Montaner, J. S.G. Related Collections Sexually transmitted infections Adverse drug reactions HIV infection, AIDS

Adverse effects of antiretroviral therapy for HIV infection

From the British Columbia Centre for Excellence in HIV/AIDS (Montessori, Press, Harris, Akagi, Montaner) and the University of British Columbia (Montessori, Press, Harris, Montaner), Vancouver, BC

Abstract

LONG-TERM REMISSION OF HIV-1 DISEASE CAN BE READILY ACHIEVED by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.

This article has been cited by other articles:

				H. R. Dalton, R. P. Bendall, F. E. Keane, R. S. Tedder, and S. Ijaz Persistent Carriage of Hepatitis E Virus in Patients with HIV Infection N. Engl. J. Med., September 3, 2009; 361(10): 1025 - 1027. [Full Text] [PDF]

				M. Y. Chowers, B. S. Gottesman, L. Leibovici, U. Pielmeier, S. Andreassen, and M. Paul Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review J. Antimicrob. Chemother., August 1, 2009; 64(2): 239 - 250. [Abstract] [Full Text] [PDF]

				P. E. Stevens and E. Hildebrandt Pill Taking From the Perspective of HIV-Infected Women Who Are Vulnerable to Antiretroviral Treatment Failure Qual Health Res, May 1, 2009; 19(5): 593 - 604. [Abstract] [PDF]

				S Kiertiburanakul, K Malathum, S Watcharananan, B Sathapatayavongs, and S Sungkanuparph Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash Int J STD AIDS, March 1, 2009; 20(3): 176 - 179. [Abstract] [Full Text] [PDF]

				S. Hariri and M. T. McKenna Epidemiology of Human Immunodeficiency Virus in the United States Clin. Microbiol. Rev., July 1, 2007; 20(3): 478 - 488. [Abstract] [Full Text] [PDF]

				Y. Saita, E. Kodama, M. Orita, M. Kondo, T. Miyazaki, K. Sudo, K. Kajiwara, M. Matsuoka, and Y. Shimizu Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist. J. Immunol., September 1, 2006; 177(5): 3116 - 3122. [Abstract] [Full Text] [PDF]

				D. C. Rudorf and S. A. Krikorian Adverse Effects Associated With Antiretroviral Therapy and Potential Management Strategies Journal of Pharmacy Practice, August 1, 2005; 18(4): 258 - 277. [Abstract] [PDF]

				K. Shannon, T. Kerr, C. Lai, T. Ishida, E. Wood, J. S. G. Montaner, R. S. Hogg, and M. W. Tyndall Nonadherence to Antiretroviral Therapy Among a Community With Endemic Rates of Injection Drug Use J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2005; 4(3): 66 - 72. [Abstract] [PDF]

				M. Hopwood and C. Treloar The Experience of Interferon-Based Treatments for Hepatitis C Infection Qual Health Res, May 1, 2005; 15(5): 635 - 646. [Abstract] [PDF]

				M. C. Zink, J. Uhrlaub, J. DeWitt, T. Voelker, B. Bullock, J. Mankowski, P. Tarwater, J. Clements, and S. Barber Neuroprotective and Anti-Human Immunodeficiency Virus Activity of Minocycline JAMA, April 27, 2005; 293(16): 2003 - 2011. [Abstract] [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2004, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.